150 related articles for article (PubMed ID: 23360626)
1. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.
Farag RE; Arafa MM; El-Etreby S; Saudy NS; Eldeek BS; El-Alfy HA; Goda IF; Ali RM
Arch Iran Med; 2013 Feb; 16(2):68-73. PubMed ID: 23360626
[TBL] [Abstract][Full Text] [Related]
2. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
3. Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C.
Marangon AV; Moliterno RA; Sell AM; de Moraes CF; Grotto RM; Pardini MC; De Pauli DS; Visentainer JE; Silva GF
Int J Immunogenet; 2012 Aug; 39(4):296-302. PubMed ID: 22284614
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
Dai CY; Chuang WL; Hsieh MY; Huang JF; Lin YY; Chu PY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antiviral Res; 2010 Feb; 85(2):396-402. PubMed ID: 19931565
[TBL] [Abstract][Full Text] [Related]
5. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
6. Prognostic effect of human leukocyte antigen class I and II alleles on chronic hepatitis C patients treated by pegylated interferon-alfa plus ribavirin in Taiwan.
Tseng KC; Chang CK; Chou AL; Hsieh YH; Tseng CA; Lai NS
Hepatogastroenterology; 2010; 57(99-100):456-61. PubMed ID: 20698208
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
9. Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
Kohjima M; Enjoji M; Yoshimoto T; Yada R; Fujino T; Aoyagi Y; Fukushima N; Fukuizumi K; Harada N; Yada M; Kato M; Kotoh K; Nakashima M; Sakamoto N; Tanaka Y; Nakamuta M
J Med Virol; 2013 Feb; 85(2):250-60. PubMed ID: 23161429
[TBL] [Abstract][Full Text] [Related]
10. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
Baur K; Mertens JC; Schmitt J; Iwata R; Stieger B; Frei P; Seifert B; Bischoff Ferrari HA; von Eckardstein A; Müllhaupt B; Geier A;
Antivir Ther; 2012; 17(3):541-7. PubMed ID: 22300961
[TBL] [Abstract][Full Text] [Related]
11. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
Miyasaka A; Kumagai I; Abe K; Suzuki K
Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
[TBL] [Abstract][Full Text] [Related]
12. IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
Estrabaud E; Appourchaux K; Bièche I; Carrat F; Lapalus M; Lada O; Martinot-Peignoux M; Boyer N; Marcellin P; Vidaud M; Asselah T
PLoS One; 2015; 10(4):e0121395. PubMed ID: 25844942
[TBL] [Abstract][Full Text] [Related]
13. [Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].
Zeng Y; Kang Y; Shang J
Zhonghua Gan Zang Bing Za Zhi; 2014 Jun; 22(6):401-6. PubMed ID: 25203700
[TBL] [Abstract][Full Text] [Related]
14. Association of HLA alleles with response (especially biochemical response) to interferon therapy in Japanese patients with chronic hepatitis C.
Nishiguchi S; Kaneshiro S; Tanaka M; Enomoto M; Akihiro T; Habu D; Takeda T; Fujino K; Tanaka T; Yano Y; Shiomi S
J Interferon Cytokine Res; 2003 Mar; 23(3):135-41. PubMed ID: 12716485
[TBL] [Abstract][Full Text] [Related]
15. Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-α and ribavirin in chronic hepatitis C virus genotype 1 infection.
Collison M; Chin JL; Abu Shanab A; Mac Nicholas R; Segurado R; Coughlan S; Connell J; Carr MJ; Merriman RB; McCormick PA; Hall WW
J Interferon Cytokine Res; 2015 Feb; 35(2):126-33. PubMed ID: 25237729
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C.
Jiao J; Wang JB
Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):80-3. PubMed ID: 15730926
[TBL] [Abstract][Full Text] [Related]
17. Role of interferon gamma and tumor necrosis factor-related apoptosis-inducing ligand receptor 1 single nucleotide polymorphism in natural clearance and treatment response of HCV infection.
Azam S; Manzoor S; Imran M; Ashraf J; Ashraf S; Resham S; Ghani E
Viral Immunol; 2015 May; 28(4):222-8. PubMed ID: 25798684
[TBL] [Abstract][Full Text] [Related]
18. Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4.
Shaker OG; Abdel-Rahim MT; Bayoumi ST
Cell Biochem Biophys; 2015 Mar; 71(2):617-25. PubMed ID: 25239021
[TBL] [Abstract][Full Text] [Related]
19. High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
Petta S; Handberg A; Marchesini G; Cammà C; Di Marco V; Cabibi D; Macaluso FS; Craxì A
J Viral Hepat; 2013 Mar; 20(3):174-82. PubMed ID: 23383656
[TBL] [Abstract][Full Text] [Related]
20. [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
Doffoël-Hantz V; Loustaud-Ratti V; Ramos-Casals M; Alain S; Bezanahary H; Liozon E; Fauchais AL; Vidal E
Rev Med Interne; 2005 Feb; 26(2):88-94. PubMed ID: 15710254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
